Optimi Health Stock Price, News & Analysis

Optimi Health Corp. is set to host a grand opening for its new psilocybin cultivation facility in Princeton, British Columbia, on May 27, 2022. Crispin Blunt, UK Conservative MP and advocate for psilocybin rescheduling, will speak on the mental health benefits of psilocybin. The facility, spanning 20,000 square feet, aims to produce EU-GMP grade psilocybin and functional mushrooms for wellness markets. Optimi has secured a research exemption and dealer's license for psilocybin use, aligning with its mission to lead in safe psychedelic therapies.

Optimi Health Corp. has acquired a diverse catalog of psilocybin and functional mushroom strains, expanding its genetic bank significantly. The acquisition, involving 24 psychedelic and nine functional strains, supports its goal of producing safe, EU-GMP psilocybin in its 20,000 square-foot facility in Princeton, British Columbia. This move allows Optimi to provide products for clinical trials and Canada’s Special Access Program. The company aims to enhance research in mental health treatment, positioning itself as a leading supplier in the burgeoning psychedelic industry.

Optimi Health Corp has completed the expansion of its analytical laboratory located in Princeton, British Columbia, designed to ensure consistent dosages of natural psilocybin products meeting FDA and EU-GMP standards. The lab, overseen by Chief Science Officer Justin Kirkland, aims to enhance research capabilities and support clients in drug discovery processes. CEO Bill Ciprick emphasized the importance of this facility for operationalizing psychedelic science and the company's revenue strategy. Optimi aims to lead in supplying safe, high-quality psilocybin mushrooms.

Optimi Health Corp. (OTCQX: OPTHF) announced its support for Health Canada's Notice on psilocybin mushrooms, highlighting the importance of drug quality and GMP standards. CEO Bill Ciprick emphasized the company's commitment to producing natural psilocybin and functional mushrooms from its advanced facilities. Optimi is positioned to become a leader in this market, having received permission to handle large quantities of psilocybin. The company will also celebrate the grand opening of its Princeton facility on May 27, inviting stakeholders from various sectors.

Optimi Health Corp. has received approval from Health Canada to modify its Controlled Substances Dealer’s Licence, allowing for an expanded capacity to produce psilocybin and psilocin at its Princeton facility. The amendment permits possession of up to 5,000 kg of dried psilocybin mushrooms and 100 g of psilocin, aiming to support clinical trials for addiction and mental health treatments. The company’s facility now comprises 20,000 square feet of advanced aeroponics systems. Optimi plans a grand opening event on May 27, 2022, inviting the local community and stakeholders.

Optimi Health Corp. is set to inaugurate its new psilocybin cultivation facility on May 27, 2022, with an event for media and stakeholders. The company aims to become the leading supplier of safe, natural psilocybin, leveraging its GMP-grade facility in Canada. With a dealer's license from Health Canada and partnerships with pharmaceutical entities, Optimi is focused on producing scalable mushroom formulations. The grand opening will be livestreamed on Instagram, welcoming community members to celebrate this significant milestone in the psychedelic industry.

Optimi Health Corp. (OTCQB: OPTHF) has initiated the cultivation of GMP-grade psilocybin mushrooms at its facility in Princeton, British Columbia. This milestone aims to supply safe psilocybin products for clinical trials amid increasing market demand. The company, having secured a Controlled Drugs and Substances Dealers License, is collaborating with the IMPACT Clinical Trial Accelerator Program for research on microdosing psilocybin to address mental health issues. A brand and media launch is set for May 2022.

Optimi Health Corp. (CSE: OPTI, OTCQB: OPTHF) has entered agreements with Kydder Management Group and Generation IACP Inc. for investor relations and market-making services, pending Canadian Securities Exchange approval. Kydder will receive $40,000 monthly for three months, with a renewal option, while GIACP will earn $7,500 monthly for six months, subject to a 3% annual price increase. Optimi is focused on developing functional mushroom products and has received a research exemption for Psilocybin and Psilocin use under Health Canada regulations.

Optimi Health Corp. (CSE: OPTI, OTCQX: OPTHF) has upgraded its common shares to the OTCQX Best Market, enhancing visibility and accessibility for U.S. investors. This upgrade signifies an important milestone for the company, which focuses on developing functional and psychedelic mushroom products for health and wellness. The OTCQX is reserved for established companies meeting high financial standards and best corporate governance practices. Optimi continues its Canadian listing under the symbol OPTI.